Company Description
Cellyan Biotechnology Co., Ltd, an investment holding company, engages in the over-the counter (OTC) pharmaceutical business in Hong Kong and Mainland China.
The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services.
It also offers customs clearance, drugs enlisting, warehouse, and other logistics services. In addition, it provides value-added services such as labeling, extended storage, product inspection, batch processing, and logistics support, as well as sales of health supplements and non-pharmaceutical products.
The company serves e-commerce platform logistics partners, merchants, and Chinese e-commerce platforms as well as pharmaceutical distributors.
The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025.
Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
| Country | Hong Kong |
| Founded | 2016 |
| IPO Date | Jan 15, 2025 |
| Industry | Medical Distribution |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Chenyu Liang |
Contact Details
Address: Well Town Industrial Building, Room B1, 5th Floor Yau Tong, 999077 Hong Kong | |
| Phone | 852 2618 9289 |
| Website | 9zt.hk |
Stock Details
| Ticker Symbol | HKPD |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 2007702 |
| CUSIP Number | G6365B104 |
| ISIN Number | KYG6365B1041 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Chenyu Liang | Chief Executive Officer and Director |
| Shu Liu | Chief Financial Officer |
| Zifeng Wang | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 7, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Jul 31, 2026 | NT 20-F | Notification of inability to timely file Form 20-F |
| Jul 16, 2026 | 6-K | Report of foreign issuer |
| Jun 24, 2026 | EFFECT | Notice of Effectiveness |
| Jun 12, 2026 | F-3 | Filing |
| Apr 8, 2026 | EFFECT | Notice of Effectiveness |
| Apr 2, 2026 | UPLOAD | Filing |
| Mar 27, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Mar 27, 2026 | 6-K | Report of foreign issuer |